Cox-2 Inhibitors Stay on the Market but Seem Out of Reach for Dx Cos | GenomeWeb

SAN DIEGO — With the Feb. 19 announcement by the US Food and Drug Administration that the drugs Celebrex and Bextra should remain on the market, data showing that higher doses of Celebrex are associated with increased cardiovascular risk may prove suddenly important to diagnostics companies with a CYP450 test capable of interrogating the 2C9 gene, which is involved in metabolizing both drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.